« Return to News | R&D Trends | Drug Sponsors

Roche buys Canadian R&D facility for $190 million

Wednesday, August 17, 2011 12:57 PM

Roche has said it intends to establish a "major global pharmaceutical development site" in Ontario, Canada, creating around 200 skilled jobs, according to PharmaTimes.

The facility in Mississauga will be set up with an investment fund of $190 million, with an additional $7.79 million provided by the Ontario Ministry of Economic Development and Trade. Renovations of the site will begin later this year and some employees have already been recruited, said Roche Canada.

Mississauga joins five other global development sites in the Roche network and will concentrate on managing operations for clinical research. The company said it selected Ontario for the facility because of its "educated and capable workforce and a favorable business environment supported by a government that places a high strategic priority on life sciences."

 Over the next five years, positions in areas such as global study management, data management and regulatory aspects of product development will be filled, and Canada will "provide global leadership and coordination for clinical development that will take place through its substantial affiliate R&D network conducting clinical trials in more than 60 countries," according to Roche.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.